Patents by Inventor Robert H. Gundel

Robert H. Gundel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of endothelial-leukocyte adhesion molecule-1 specific antibodies in the treatment of asthma
    Patent number: 5843441
    Abstract: A method for treating asthma in a patient using an agent selected from the group consisting of:(a) an antibody capable of binding to ELAM-1;(b) a fragment of the antibody (a), the fragment being capable of binding to ELAM-1;(c) ELAM-1, being substantially free of natural contaminants;(d) a functional derivative of ELAM-1;(e) an antibody capable of binding to an ELAM-1 receptor;(f) a fragment of the antibody (e), the fragment being capable of binding to an ELAM-1 receptor;(g) an ELAM-1 receptor, being substantially free of natural contaminants; and .(h) a functional derivative of an ELAM-1 receptor.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: December 1, 1998
    Assignee: Boehringer Ingelheim
    Inventors: Robert H. Gundel, Craig D. Wegner, L. Gordon Letts, C. Wayne Smith
  • Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
    Patent number: 5730983
    Abstract: The present invention relates to the use of intercellular adhesion molecule-1 (ICAM-1) or fragments thereof, anti-CD18 antibodies or fragments thereof, and members of the CD18 family of proteins or fragments thereof in the treatment of asthma.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: March 24, 1998
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Craig D. Wegner, Robert H. Gundel, Robert Rothlein
  • Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
    Patent number: 5324510
    Abstract: The present invention provides a method of reducing the severity of asthma. Specifically, the present invention discloses that anti-adhesion antibodies, such as anti-ICAM-1 or anti-CD18 family member antibodies, when administered to a mammal, are capable of decreasing the hyperresponsive reaction associated with an asthmatic response.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: June 28, 1994
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Craig D. Wegner, Robert H. Gundel, Robert Rothlein